Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis

Background: Apatinib is a novel tyrosine kinase inhibitor used in the treatment of advanced hepatocellular carcinoma (HCC). For decades, sorafenib has been a classic first-line treatment option for patients with HCC. This meta-analysis aimed to assess the efficacy and safety of apatinib versus soraf...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Dan, Cai, Yongqing, Chen, Geng, Hou, Min, Luo, Xiaofeng, Dongzhi, Zhuoma, Xie, Hongjun, Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160361/
https://www.ncbi.nlm.nih.gov/pubmed/37153777
http://dx.doi.org/10.3389/fphar.2023.1101063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160361/
https://www.ncbi.nlm.nih.gov/pubmed/37153777
http://dx.doi.org/10.3389/fphar.2023.1101063

Ejemplares similares